Clinical Trial Update: Combination of DV and Tislelizumab for Renal Preservation in High-risk UTUC Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of DV and tislelizumab for renal preservation in high-risk upper urinary tract urothelial carcinoma; status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Upper Urinary Tract Urothelial Carcinoma

Drugs mentioned

• DV
• Tislelizumab (tislelizumab)

Snippet

Sponsor: RenJi Hospital | Conditions: Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation | Phase 2 | Status: RECRUITING